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AbstrAct
Objective To identify the role of mature nerve growth 
factor (mNGF), its immature form proNGF and their 
receptors in arthritis inflammation.
Methods Real-time PCR, western blot and ELISA were 
performed to evaluate NGF, proNGF, their receptor and 
cytokine expression in synovial tissue and cells of patients 
with juvenile idiopathic arthritis (JIA) and rheumatoid 
arthritis (RA), and controls.
Results proNGF and not mNGF is the prevalent form 
measured in synovial fluids of patients with JIA and RA 
with synovial fibroblasts as a major source of proNGF 
in the inflamed synoviae. p75NTR, the specific receptor 
for proNGF, is the NGF receptor most expressed in 
mononuclear cells of patients with JIA, while TrkA is 
the prevalent receptor in healthy donors. In ex vivo 
experiments the effects of proNGF differ from those 
of mNGF, suggesting that the balance of p75NTR and 
TrkA expression represents a critical factor in regulating 
mNGF/proNGF functions, determining which intracellular 
pathways and biological activities are triggered. Contrary 
to NGF, proNGF administration increased inflammatory 
cytokines but not interleukin (IL)-10 expression, inducing 
a stronger activation of p38 and JNK pathways. proNGF 
effects depend on its binding to p75NTR, as inhibition 
of p75NTR with neutralising antibodies or LM11A-31 
abolished proNGF-induced production of IL-6 in patients’ 
mononuclear cells, while inhibition of TrkA did not. There 
is a correlation in patients with arthritis between high 
p75NTR levels and severity of clinical symptoms.
Conclusions Our data suggest that an active proNGF-
p75NTR axis promotes proinflammatory mechanisms 
contributing to chronic tissue inflammation, and that the 
use of p75NTR inhibitors may represent a new therapeutic 
approach in chronic arthritis.
IntROduCtIOn
High levels of nerve growth factor (NGF) 
characterise inflamed tissues of patients with 
a variety of chronic inflammatory diseases,1–3 
but how NGF and the activation of its recep-
tors, TrkA and p75NTR, regulate cells and 
mediators during inflammatory responses is 
not yet well defined.
We recently demonstrated in human mono-
cytes that inflammatory stimuli, while acti-
vating a proinflammatory response through 
Toll-like receptors (TLR), also upregulate 
the expression of the NGF receptor TrkA.4 
TrkA activation inhibits TLR signalling, and 
this results in a decrease in inflammatory 
cytokines and a concomitant increase in 
anti-inflammatory cytokine production. A 
marked downregulation of TrkA expression 
characterises mononuclear cells of patients 
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Key messages
What is already known about this subject?
 ► High levels of nerve growth factor (NGF) have been 
demonstrated in patients with arthritis, but there 
is no clear evidence of NGF-specific effects on the 
inflammatory response.
 ► Moreover, no information is available on the role of 
the other NGF form, the proNGF, and its preferential 
receptor system p75NTR/sortilin in inflammatory 
diseases.
What does this study add?
 ► This study shows for the first time that in inflamed 
synoviae the high levels of proNGF, with activated 
synovial fibroblasts as its major source, and high 
levels of p75NTR, the specific receptor of proNGF, 
correlate with the severity of clinical symptoms in 
patients with arthritis.
How might this impact on clinical practice?
 ► The in vitro data showing that binding of proNGF 
to p75NTR enhances inflammatory cytokine 
production and that inhibition of p75NTR activity 
reduces inflammation suggest that inhibitors 
of p75NTR could represent a new therapeutic 
approach in chronic arthritis.
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with juvenile idiopathic arthritis (JIA), who showed an 
altered NGF regulatory feedback mechanism: in contrast 
to observations in healthy donors, the addition of NGF 
did not reduce interleukin (IL)-6 production from JIA 
mononuclear cells.4
To assess whether there were other anomalies in the 
NGF pathways of patients with JIA, in this study we 
investigated the modulation of the other NGF receptor, 
p75NTR, during the inflammatory response in patients 
with arthritis and how its engagement affected inflam-
mation. Initially defined as the low-affinity NGF receptor, 
p75NTR was believed to bind to TrkA, increasing both 
TrkA specificity and affinity for NGF, thus contributing to 
the creation of a high-affinity NGF receptor.5 Currently, 
the role of p75NTR appears to be much more complex, 
and studies on its effects and signalling pathways, 
restricted mainly to cells of the nervous system, have 
not fully defined it. This is quite surprising, considering 
that p75NTR was the first characterised member of the 
tumour necrosis factor (TNF)-receptor superfamily,6 
whose members share structural similarities, such as an 
intracellular ‘death domain’ and the lack of intrinsic 
enzymatic activity, and play a crucial role in the homeo-
stasis of the immune system.7 8 As in other members of 
this receptor family, p75NTR has been reported to have 
different, or even opposite, effects depending on envi-
ronment and cell type. Indeed, studies on neuronal 
cells have shown that p75NTR can either induce apop-
tosis or favour survival in differentiating neurons and 
affects cytoskeleton organisation, neurite growth and 
axonal degeneration.9 This variety of effects is mediated 
by many cytosolic interactors and a growing number of 
coreceptors.9 10 Recently, much attention has been paid 
to sortilin, a transmembrane receptor belonging to the 
Vps10p domain-receptor family11 that, in addition to its 
role in regulating protein trafficking, specifically binds 
proNGF, the immature form of NGF, increasing the spec-
ificity and affinity of p75NTR for proNGF.12
Studies on neurons have suggested that proNGF is not 
an inactive precursor,13 but acts as a signalling ligand with 
effects that are distinct from or even opposite to those 
of mature nerve growth factor (mNGF).14 Notably, in vivo 
studies have shown that proNGF can be even more abun-
dant than mNGF in brain and in peripheral tissues.15 16
No information is available on the effects of the 
binding of proNGF to p75NTR in regulating the immune 
response. The main aim of this study was to investigate 
the potential involvement of the proNGF-p75NTR axis in 
chronic arthritides and the effects of proNGF through the 
p75NTR receptor on mononuclear cells from inflamed 
joints. Our results indicate that mononuclear cells of 
patients with JIA show an altered p75NTR/TrkA balance 
that, together with the high concentration of proNGF 
found in inflamed synovia, contributes to activate inflam-
matory pathways, leading to enhanced production of 
inflammatory cytokines. The blocking of p75NTR in ex 
vivo experiments with JIA mononuclear cells strongly 
suggests that the relative levels of p75NTR expression 
play a key role in the inflammatory response and provide 
the rationale for specifically targeting p75NTR for the 
treatment of chronic inflammatory diseases.
MateRIals and MetHOds
Patients
Diagnosis of JIA and classification into JIA subtypes was 
based on the International League of Associations for Rheu-
matology classification criteria. Patients were classified as 
persistent oligoarticular, extended oligoarticular or polyar-
ticular JIA. The median age at disease onset was 3.0 years 
(IQR 2.1–6.7) and the median disease duration at sampling 
was 5.0 years (IQR 1.9–8.7). All patients had active disease at 
the time of sampling. Patients receiving systemic glucocor-
ticoids were not included in the study. Approximately 50% 
of the patients were receiving methotrexate with or without 
associated TNF inhibitors, with the remaining patients 
being treated with non-steroidal anti-inflammatory drugs 
only. Incidentally, no differences in p75NTR expression 
were found among the two groups. Synovial fluid samples 
were obtained at the time of intra-articular steroid injection. 
The study was approved by the Ethical Committee of the 
Bambino Gesù Children’s Hospital and written consent was 
obtained from parents of children as appropriate. Periph-
eral blood from healthy children of comparable age who 
underwent routine blood sampling prior to minor elective 
surgery for malformations were used as controls. Synovial 
tissue was obtained from patients with rheumatoid arthritis 
(RA) undergoing ultrasound-guided synovial biopsy at the 
Division of Rheumatology of the IRCCS Policlinico S Matteo 
Foundation, Pavia, Italy. Fibroblast-like synoviocytes (FLS) 
were obtained from patients with RA and osteoarthritis 
(OA) after synovial biopsy.17 Fibroblasts obtained from skin 
of healthy donors were used as controls.
Cell cultures
Mononuclear cells were isolated from peripheral blood 
(PBMC) and from synovial fluids (SFMC) of patients with 
JIA by Ficoll-Hypaque (Pharmacia, Uppsala, Sweden). 
Cells were cultured in AIM V Serum Free Medium (Life 
Technologies, Rockville, Maryland, USA) either without 
the addition of any stimuli (unstimulated, US) or activated 
with 3 ng/mL Lipopolysaccharide (LPS, Sigma Aldrich, St 
Louis, Missouri, USA). Mononuclear cells were treated 
with or without mNGF or mutated cleavage-resistant 
proNGF (Alomone Labs, Jerusalem, Israel) at a concen-
tration, respectively, of 100 ng/mL and 200 ng/mL, calcu-
lated to yield the same molar concentration as described 
in neurons.18 For this study we selected an endotoxin-free 
proNGF to avoid unspecific activation of mononuclear 
cells. To block p75NTR and TrkA activity, the cells were 
incubated with either 2.5 µg/mL affinity-purified anti-
p75NTR antibody (Millipore, Billerica, Massachusetts, 
USA) or 10 nM LM11A-31 (Dompé Farmaceutici, L’Aq-
uila, Italy) or 3 µg/mL affinity-purified anti-TrkA antibody 
(R&D Systems, Minneapolis, Minnesota, USA) for 1 hour 
and then stimulated with 2 ng/mL LPS with or without the 
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Figure 1 p75NTR, TrkA and sortilin expression levels in patients with JIA. (A) mRNA expression levels of TrkA, p75NTR and 
sortilin in freshly isolated mononuclear cells from peripheral blood of healthy children (CTRL PBMC) and in mononuclear cells 
from peripheral blood or from synovial fluids of patients with JIA (respectively, JIA PBMC and JIA SFMC) were quantified 
by real-time PCR analysis. JIA PBMC (n=34) and JIA SFMC (n=66) express low TrkA and high p75NTR mRNA levels 
compared with CTRL PBMC (n=10). Sortilin, a coreceptor for p75NTR essential for proNGF binding, is highly expressed in 
JIA SFMC (n=19) and expressed in JIA PBMC (n=13) and in CTRL PBMC (n=7). The results are expressed as arbitrary units 
(AU) after normalisation with the housekeeping gene GAPDH. (B) p75NTR mRNA levels are higher in SFMC than in PBMC 
of matched patients with JIA (n=18).  (C) Sortilin mRNA levels are higher in SFMC than in PBMC of matched patients with 
JIA (n=11). (D) Western blot and densitometric analysis of three independent experiments confirmed that p75NTR was the 
prevalent NGF receptor in JIA mononuclear cells , while TrkA was the most expressed NGF receptor in CTRL PBMC. Sortilin 
is also highly expressed in JIA mononuclear cells. *p<0.05, **p<0.01, ***p<0.001. JIA, juvenile idiopathic arthritis; NGF, nerve 
growth factor; PBMC, mononuclear cells isolated from peripheral blood; SFMC, mononuclear cells isolated from synovial fluids.
addition of 200 ng/mL proNGF. FLS was obtained from 
synovial tissue of patients with RA (RA FLS) or patients with 
OA (OA FLS) after enzymatic digestion with 0.2% colla-
genase type IV in high-glucose Dulbecco's Modified Eagle 
Medium (DMEM) supplemented with 10% fetal calf serum 
and antibiotics. Isolated synovial cells were expanded in 
DMEM supplemented with 10% FCS and used between 
the third and sixth passage. All fibroblasts were then 
cultured for 18 hours at a concentration of 50 000 cells/
mL in serum-free Medium 106 (Thermo Fisher Scientific, 
Waltham, Massachusetts, USA) only.
Rna extraction and real-time PCR analysis
Total RNA, extracted from cells and tissues using TRIzol 
Reagent (Life Technologies), was used for first-strand 
cDNA synthesis (SuperScript VILO cDNA Synthesis Kit; 
Invitrogen, Carlsbad, California, USA). Freshly puri-
fied  mononuclear cells obtained from peripheral blood 
or synovial fluid after Ficoll gradient centrifugation 
were used to measure mRNA expression levels of TrkA, 
p75NTR and sortilin in patients with JIA and healthy 
donors (controls CTRL) (figure 1A,B) and to associate 
them with disease activity (figure 3). FLS obtained from 
group.bmj.com on September 13, 2017 - Published by http://rmdopen.bmj.com/Downloaded from 
4 Minnone G, et al. RMD Open 2017;3:e000441. doi:10.1136/rmdopen-2017-000441
RMD Open
RA FLS, from OA FLS or control fibroblasts obtained 
from skin of healthy donors (CTRL FB) were used to 
analyse NGF mRNA expression levels and were untreated 
(figure 2D). For cytokine mRNA expression (figure 4C), 
mononuclear cells from synovial fluid (SFMC) or from 
peripheral blood (PBMC) of patients with JIA and mono-
nuclear cells from peripheral blood of healthy controls 
were cultured for 3 hours before RNA extraction in AIM 
V serum-free medium only (US conditions) or treated 
with LPS (3 ng/mL), with or without the addition of 
mutated proNGF (200 ng/mL) or mNGF (100 ng/
mL). Real-time PCR was performed on the ABI PRISM 
7900 HT Sequence Detector (Applied Biosystems, 
Foster City, California, USA) platform, using TaqMan 
Universal Master Mix (Applied Biosystems). TrkA, 
p75NTR, NGF, sortilin, IL-1β, IL-6, IL-8, IL-10 and TNF-α 
mRNA expressions were tested using Assays on Demand 
reagents (TrkA Hs01021011_m1; p75NTR Hs00182120_
m1; NGF Hs00171458_m1; sortilin Hs00361760_m1; 
IL-1β Hs00174097_m1; IL-6 Hs00985639_m1; IL-8 
Hs00174103_m1; IL-10 Hs00961622_m1; TNF-α 
Hs99999043_m1; Applied Biosystems). TaqMan Endoge-
nous Control human GAPDH (Hs99999905_m1; Applied 
Biosystems) was used as housekeeping gene. Relative 
quantification was performed using the comparative Ct 
method and results were expressed in arbitrary units 
(AU). Expression levels were calculated as 2−ΔCt and then 
compared with each other, while fold changes were calcu-
lated using the 2−ΔΔCt equation.19
Cytokine and mnGF-pronGF elIsa
Conditioned media were collected from mononuclear cells 
obtained from peripheral blood (PBMC) and from synovial 
fluid (SFMC) of patients with JIA and from RA, OA and skin 
fibroblasts (FLS) after 18 hours of incubation in synthetic 
medium without any kind of stimulation (US). Condi-
tioned media of mononuclear cells of patients with JIA and 
healthy donors treated with LPS, with or without the addi-
tion of either proNGF or mNGF, were also collected and all 
conditioned media were stored at −80°C. Human IL-6 was 
measured using ELISA kit (R&D Systems). Concentrations 
of mNGF and proNGF were analysed using specific ELISAs 
developed by the Consiglio Nazionale delle Ricerche 
(CNR) group and recently described.20 In brief, to recog-
nise mNGF and proNGF the AF-556 capture antibody (R&D 
Systems) was coated overnight at room temperature (RT). 
After blocking for 1 hour at RT with phosphate buffered 
saline (PBS) +1% Bovine Serum Albumin (BSA), samples 
were incubated for 2 hours at RT. The microwells were then 
incubated with EP1318Y-proNGF (Chemicon) or 27/21-
mNGF (Chemicon) detection monoclonal antibodies 
dissolved in blocking buffer for 2 hours at RT. Horseradish 
peroxidase (HRP)-conjugated antibodies (Cell Signaling, 
Danvers, Massachusetts, USA) were added and incubated 
for 1 hour at RT. To visualise antibody reactivity, the chro-
mogenic substrate 3’,3’,5,5’-tetramethylbenzidine (TMB, 
Sigma Aldrich) was used and colour development was 
stopped by adding 1N HCl. The colourimetric reaction was 
measured in absorbance mode at 450 nm by a Multiskan EX 
ELISA reader (Thermo Fisher Scientific Laboratory Equip-
ment, Hudson, New Hampshire, USA).
Western blot analysis
Mononuclear cells from synovial fluid (SFMC) of patients 
with JIA in AIM V serum-free medium were either treated 
with 3 ng/mL LPS and 200 ng/mL proNGF for 5 or 
10 min or not treated (US). For p75NTR inhibition, cells 
were starved for 3 hours in Roswell Park Memorial Insti-
tute medium (RPMI) 0.1% FCS, preincubated with 10 nM 
LM11A-31 for 1 hour in AIM V serum-free medium and 
then stimulated with LPS, with or without the addition 
of 50 ng/mL NGF or 100 ng/mL mutated-proNGF for 
5 min. After cell lysis in ice-cold RIPA buffer (Cell Signa-
ling), equal amounts of protein were resolved by Sodium 
Dodecyl Sulphate - PolyAcrylamide Gel Electrophoresis 
(SDS-PAGE) and electrotransferred to nitrocellulose 
membranes. The total protein loading for synovial fluids 
(see figure 2A,B) was assessed by Ponceau staining (not 
shown) and gel analysis by the National Institutes of 
Health (NIH)  ImageJ software. The amount of loaded 
proteins for synovial fluids was found to be almost equal 
for all the samples run on SDS-PAGE (coefficient of vari-
ation=5.81%). Nitrocellulose membranes (Amersham 
Life Sciences, Little Chalfont, UK) were probed with anti-
bodies against phospho-stress-activated protein kinase/
c-Jun NH(2)-terminal kinase (SAPK/JNK) (Thr183/
Tyr185), and total SAPK/JNK, phospho-p38 MAPK 
(Thr180/Tyr182) and total p38 MAPK (all from Cell 
Signaling), p75NTR (clone 8211) (EMD Millipore, Bill-
erica, Massachusetts, USA), TrkA (sc-118) and GAPDH 
(all from Santa Cruz Biotechnology, Dallas, Texas, USA) 
and tubulin (Sigma Aldrich). To evaluate the relative 
concentrations of proNGF and mNGF in synovial fluids 
of patients with arthritis, we used the rabbit polyclonal 
antibody mNGF H-20 (SantaCruz sc-548 WB) that recog-
nises immunoreactive NGF forms ranging from 13 to 
150 kDa after SDS-PAGE in reducing conditions.20 Nitro-
cellulose-bound antibodies were detected by chemilumi-
nescence with ECL (Amersham Life Sciences).
statistical analysis
Statistical analysis of the results was performed using 
non-parametric tests (GraphPad Prism 5 Software, La 
Jolla, California, USA). Data are presented as mean±SEM 
or SD as appropriate, and the level of statistical signifi-
cance was set at p<0.05.
Results
 p75ntR, sortilin and pronGF expression in patients with JIa 
and Ra
In patients with JIA (n=70) the p75NTR receptor is highly 
expressed: the mean expression of p75NTR was twofold 
higher in mononuclear cells from peripheral blood 
(PBMC) and 19-fold higher in mononuclear cells from 
synovial fluids (SFMC) than in control PBMC (p<0.05 and 
p<0.001, respectively, Figure 1A). The analysis of paired 
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Figure 2 Mature and immature NGF forms in patients with JIA and RA. (A,B) Only proNGF forms of different molecular 
weights but not mature NGF were detected by western blot in synovial fluids of 12 patients with JIA (40 μg total protein). (B) 
Blocking the anti-NGF antibody by adding mature NGF results in the disappearance of the specific proNGF bands observed 
in synovial fluids of three patients with JIA, as well as of the band of the 25 kDa commercial proNGF that was added as 
positive control. (C) In JIA and RA synovial fluids, proNGF and mature NGF (mNGF) concentrations were assessed using a 
newly developed ELISA showing that proNGF is 4.8-fold higher in JIA (n=27) and 16.8-fold higher in patients with RA (n=5) 
than mNGF. (D) Real-time PCR shows a very low expression of NGF mRNA in mononuclear cells obtained from peripheral 
blood of healthy donors (CTRL PBMC) or in mononuclear cells from peripheral blood (JIA PBMC) and from synovial fluids of 
patients with JIA (JIA SFMC). High NGF mRNA expression levels characterised synovial tissues (RA synovia; n=5). Fibroblast-
like synoviocytes (FLS; n=3) of patients with RA express more NGF mRNA than FLS from osteoarthritis patients (OA FLS) 
(n=4) and control fibroblasts (CTRL FB; n=4). Results were expressed as arbitrary units (AU) and obtained after normalisation 
with the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH). (E) Both unstimulated (US) and LPS-
stimulated JIA SFMC do not release proNGF or mNGF in the supernatants. Commercial proNGF and mNGF were added as 
positive controls. (F) Western blot shows the stability of exogenous added mNGF and proNGF. After its addition to culture 
media, proNGF is still detected after 3 hours and undergoes a minor maturation into mNGF in the first 2 hours of incubation 
(left side of F). mNGF is not degraded in the first 3 hours after its addition (right side of F). Commercial proNGF and mNGF 
were included as positive controls. (G) Neither proNGF nor mNGF were released in culture media of US or LPS-stimulated JIA 
SFMC after 18 hours of incubation. Exogenous proNGF or mNGF were detected only at time of supplementation (in agreement 
with F) but were no longer detectable after 18 hours of incubation. Commercial proNGF and mNGF were included as positive 
controls. (H) ELISA instead shows that conditioned media of RA FLS (n=5) have higher concentrations of proNGF than control 
fibroblasts (CTRL FB; n=5) and that the concentration of proNGF is higher than mNGF after 18 hours of incubation. *p<0.05, 
**p<0.01, ***p<0.001. JIA, juvenile idiopathic arthritis; LPS, Lipopolysaccharide; NGF, nerve growth factor; PBMC, mononuclear 
cells isolated from peripheral blood; RA rheumatoid arthritis; SFMC, mononuclear cells isolated from synovial fluids.
samples of PBMC and SFMC in 18 patients with JIA 
showed that SFMCs are characterised by a significant 
upregulation of p75NTR expression (p<0.001) when 
compared with PBMC of the same patients (Figure 1B). 
Confirming our previous results on a smaller group of 
patients,4 the expression of TrkA in PBMC from patients 
with JIA was significantly lower than in control PBMC 
(p<0.01) and, even at the site of inflammation, TrkA 
expression levels in SFMC remained significantly lower 
(p<0.05) than those of healthy children (Figure 1A). The 
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Figure 3 p75NTR and disease severity (A) in persistent oligoarticular (n=29), extended oligoarticular (n=16) and polyarticular 
(n=13) patients p75NTR mRNA expression levels are higher in patients with JIA with the highest number of inflamed joints 
(**p<0.01). (B) p75NTR mRNA levels found in SFMC of patients with JIA (n=57) correlate with the number of active joints 
(rs=0.43; p=0.001) and (C) with C reactive protein levels (n=50; rs=0.39; p=0.006). JIA, juvenile idiopathic arthritis; SFMC, 
mononuclear cells isolated from synovial fluids.
concomitant increase in p75NTR expression and decrease 
in TrkA expression determined an abnormal receptor 
balance: in PBMC of healthy donors the p75NTR/TrkA 
expression ratio was 0.5±0.09, while in patients with 
JIA it was 2.4±0.11 in PBMC (p<0.01) and 13.1±1.1 in 
SFMC (p<0.001). Consistently, western blot clearly indi-
cated that p75NTR, and not TrkA, was the predominant 
receptor in JIA mononuclear cells, in contrast to control 
PBMC, where TrkA, and not p75NTR, is the prevalent 
NGF receptor (Figure 1D). Moreover, in agreement with 
real-time PCR data, JIA SFMCs express higher p75NTR 
protein levels than JIA PBMCs (Figure 1D). Mononu-
clear cells also express sortilin, the p75NTR coreceptor, 
and its expression level was markedly increased in JIA 
SFMCs, which also have the highest p75NTR expression 
(Figure 1A). Similarly to p75NTR, in paired JIA samples 
sortilin expression is significantly higher (p<0.01) in 
SFMC than in PBMC (Figure 1C). In western blot, JIA 
mononuclear cells showed higher levels of sortilin than 
healthy controls (Figure 1D).
Since studies on neuronal cells have shown that sortilin 
and p75NTR coexpression increases the specificity and 
affinity of p75NTR to proNGF,12 contributing to the 
formation of high-affinity receptors for NGF, we investi-
gated whether the preferential ligand of p75NTR, that is 
proNGF, was present in the synovial fluids of patients with 
JIA and RA. Using an anti-NGF antibody that recognises 
both mature and immature human NGF forms,20 we 
found that the predominant form of NGF in the syno-
vial fluid of patients with JIA was proNGF, while mNGF 
was not detectable by western blot (Figure 2A,B). In 
agreement with previous reports,20–22 we found that the 
majority of proNGF forms detectable in synovial fluid 
weighed 50, 34 and 25 kDa, the two latter probably repre-
senting the proNGF-A and proNGF-B splicing variants, 
respectively,21 23 while the 50 kDa could represent a glyco-
sylated proNGF24 or a dimer of the proNGF-B. To quan-
tify more accurately the concentration of both proNGF 
and mNGF, we used ELISAs that specifically recognise 
either the immature (ie, proNGF) or the mature form of 
human NGF.20 Confirming the western blot results, the 
concentration of proNGF far exceeded that of mNGF in 
synovial fluids of patients with JIA and RA (Figure 2C).
In order to identify the cellular source of proNGF, we 
found that NGF mRNA expression was very low in PBMC 
and SFMC from patients, while in PBMC from healthy 
donors (n=8) NGF expression was not detectable in our 
real-time PCR experimental conditions (Figure 2D). 
The protein analysis showed that SFMC did not release 
proNGF or mNGF in the culture media, neither in 
unstimulated conditions nor after LPS stimulation 
(Figure 2E). In the conditioned media of LPS-treated 
cells, the only detectable NGF forms were those exog-
enously added (Figure 2F,G). In order to assess the 
stability of mNGF and of the cleavage-resistant proNGF 
in our culture conditions, we collected conditioned 
media at different time points (Figure 2F,G). We found 
that up to 3 hours after LPS activation (Figure 2F), the 
time at which we collected cells for real-time PCR analysis 
of cytokine expression, there is any appreciable degra-
dation of proNGF and mNGF, while neither NGF form 
was detectable after 18 hours of incubation (Figure 2G). 
This suggests that proNGF and mNGF could exert their 
specific biological role on cultured cells, inducing their 
peculiar signature pattern of gene expression.14
To further evaluate the synthesis of NGF in the inflamed 
tissue, we used synovial tissues from adult patients with 
RA, since synovial tissues were not available from children 
with JIA (there being no clinical indication for synovial 
biopsies in JIA). In RA synoviae NGF mRNA expression 
is extremely high (Figure 2D). Using FLS obtained from 
synoviae of patients with RA (RA FLS) we found that 
these cells have a markedly higher expression (p<0.05) of 
NGF mRNA than fibroblasts obtained from patients with 
OA (OA FLS), a degenerative joint disease characterised 
by the absence of chronic inflammation, and control 
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fibroblasts obtained from skin (CTRL FB; Figure 2D). 
These results clearly indicate that, in the inflamed syno-
viae, activated fibroblasts and not SFMC are the main 
NGF producers. Consistent with the findings in JIA syno-
vial fluid (Figure 2A,B) showing proNGF as the predom-
inant form of NGF, we found that RA FLS secreted high 
levels of proNGF and the amount of proNGF in the 
conditioned media of RA FLS far exceeded (p<0.001) 
the concentration of mNGF (Figure 2H).
sFMC p75ntR mRna levels correlate with disease activity
To evaluate the association of p75NTR mRNA expres-
sion with disease severity, we divided patients according 
to subtypes, with polyarticular JIA being the most severe 
and oligoarticular JIA the milder disease. We found that 
SFMC mRNA p75NTR expression levels were highest 
in patients with polyarticular JIA (n=13) and lowest in 
patients with persistent oligoarticular JIA (n=29; p<0.01), 
with patients with extended oligoarticular JIA (n=16) 
having intermediate levels (Figure 3A). In order to eval-
uate the association with disease activity at the time of 
sampling, we analysed the correlation of p75NTR mRNA 
expression levels with the number of joints of active 
arthritis, as an estimate of the clinical disease burden, 
and with C reactive protein (CRP) levels, as a biochemical 
measure of the degree of inflammation. We found that 
p75NTR mRNA expression levels in SFMC were signif-
icantly correlated with the number of joints with active 
arthritis at sampling (rs=0.43, p<0.001) (Figure 3B). In 
order to confirm the difference between patients with a 
low number of joints with active arthritis and those with 
a high number of joints with active arthritis, we used a 
cut-off of 4 joints, which is generally accepted in JIA. We 
found that patients with ≥5 joints with active arthritis 
had expression levels of p75NTR (0.053 AU), markedly 
higher than those of patients with ≤4 joints with active 
arthritis (0.013 AU). We also found that p75NTR mRNA 
expressions were correlated with levels of CRP (rs=0.39; 
p<0.006) (Figure 3C). These results show that high levels 
of p75NTR mRNA expression at sites of inflammation 
are associated with the most severe subtype and with clin-
ical and biochemical inflammatory disease activity. Inci-
dentally, we also find in SFMC a significant positive corre-
lation between the p75NTR/TrkA ratio and CRP levels 
(p=0.01, rS=0.3), erythrocyte sedimentation rate (p=0.04 
rS=0.3) and the number of joints with active arthritis at 
sampling (p=0.03 rS=0.025), suggesting an active role of 
p75NTR axis during inflammation.
effects of pronGF on cytokine production by JIa mononuclear 
cells
High levels of p75NTR and proNGF characterise the site 
of inflammation in patients with JIA, but our current 
understanding of the proNGF-p75NTR axis does not 
offer any data on the possible role of proNGF in the 
inflammatory response. Since in neuronal cells the 
binding of proNGF to p75NTR/sortilin appears to induce 
apoptosis,12 25 we first evaluated whether the addition of 
proNGF to SFMC affected cell survival. The addition of 
200 ng/mL proNGF to SFMC, which are characterised 
by high p75NTR and low TrkA expression, did not alter 
the survival of US or LPS-stimulated cells. Similar results 
were obtained following the addition of 100 ng/mL NGF 
(figure 4A).
We then evaluated whether proNGF affected the 
expression of inflammatory cytokines in mononuclear 
cells of patients with JIA and healthy controls. Similar 
to what we have already demonstrated using mNGF,4 in 
the absence of TLR4 activation with LPS, the addition 
of increasing amounts of endotoxin-free proNGF did 
not induce a significant increase in the release of IL-6 
in freshly isolated PBMC of healthy controls (data not 
shown). There was no dose-dependent induction either 
in PBMC (data not shown) or in SFMC of patients with 
JIA (figure 4B), the latter expressing the highest levels of 
p75NTR, the specific proNGF receptor (see Figure 1A). 
On the contrary, only when JIA SFMC were costimulated 
with LPS and proNGF did we observe a dose-dependent 
increase in the release of IL-6, with a maximal effect at 
a concentration of 200 ng/mL of proNGF (figure 4B). 
Interestingly, the effects of mNGF addition to LPS-acti-
vated PBMC and SFMC of patients with JIA were different 
from those of proNGF, as mNGF did not significantly 
modify IL-6 mRNA expression (figure 4C), an observa-
tion that is in line with the previously described inability 
of mNGF to modulate IL-6 production in JIA mononu-
clear cells.4 Analysis of IL-6 secreted by SFMC confirmed 
that the addition of proNGF, but not of mNGF, results 
in increased IL-6 release (figure 4D). Incidentally, we 
also found that the addition of proNGF to LPS-acti-
vated SFMC induces increased expression of mRNA for 
IL-1β, IL-8 and TNF-α (figure 4C), an effect that was not 
observed with the addition of mNGF to LPS-activated 
SFMC (figure 4C). In these cells, characterised by high 
p75NTR expression, neither proNGF nor mNGF can 
upregulate IL-10 mRNA expression, which can instead 
be significantly induced in control PBMC, expressing 
high TrkA but low p75NTR, by mNGF but not by proNGF 
(figure 4C).
To assess whether the effect of proNGF on inflammatory 
cytokine release is dependent on the binding to p75NTR 
or to TrkA, SFMCs were incubated with neutralising anti-
bodies against p75NTR or TrkA. In LPS-activated SFMC, 
the p75NTR blocking resulted in a significant reduc-
tion in IL-6 release induced by proNGF (figure 5A). 
This finding was confirmed using the pharmacological 
inhibitor LM11A-31, a selective non-peptide ligand of 
p75NTR, which specifically blocks the binding site of 
p75NTR for proNGF.26 On the contrary, IL-6 induction 
by proNGF is not affected when TrkA activity is inhibited 
with a neutralising antibody (figure 5A), confirming the 
key role of p75NTR in mediating proNGF activity inde-
pendently of TrkA.
Analysis of the pathways involved in p75NTR signal-
ling showed that, in LPS-treated SFMC, the addition of 
proNGF induced an enhanced phosphorylation of p38 
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Figure 4 Ex vivo effects of proNGF and NGF on JIA mononuclear cells. (A) No changes in cell viability were observed 
when mononuclear cells from synovial fluid (SFMC) of patients with JIA were treated for 24 hours with proNGF or mNGF, 
with or without LPS stimulation. Apoptosis was assessed by Annexin V flow cytometry analysis. The results represent one 
of three independent experiments performed in duplicate. (B) While proNGF addition alone did not induce the production of 
interleukin (IL)-6 in unstimulated SFMC, in LPS-activated cells proNGF induced IL-6 release in a dose-dependent manner 
with a maximal effect at 200 ng/mL (n=4). (C) proNGF stimulation significantly increased IL-6, IL-1β, IL-8 and tumor necrosis 
factor-α (TNF-α) mRNA expression levels in LPS-stimulated SFMC (n=18) of patients with JIA after 3 hours of incubation, but 
did not modify IL-10 mRNA expression in either CTRL or JIA mononuclear cells. Mature NGF treatment did not significantly 
modify proinflammatory cytokine levels or IL-10 mRNA expression in JIA mononuclear cells, while it increased IL-10 mRNA 
levels in CTRL PBMC. Results are expressed as arbitrary units (AU) and obtained after normalisation with the housekeeping 
gene GAPDH. (D) proNGF treatment significantly increased IL-6 release after 18 hours (measured by ELISA) in LPS-
stimulated SFMC from patients with JIA (n=16) compared with PBMC of healthy CTRL (n=6). Mature NGF treatment did 
not affect IL-6 protein levels. *p<0.05. JIA, juvenile idiopathic arthritis; LPS, Lipopolysaccharide; NGF, nerve growth factor; 
PBMC, mononuclear cells isolated from peripheral blood.
and JNK, which are part of the signalling pathways involved 
in inflammatory cytokine production (figure 5B). In 
contrast, the addition of NGF did not induce phosphor-
ylation of p38 or JNK. A reduction in p38 and JNK phos-
phorylation was observed when the inhibitor LM11A-31 
was added together with proNGF, demonstrating that 
blocking of the binding of proNGF to p75NTR inhibits 
signalling through classical proinflammatory pathways 
(figure 5C).
Altogether these results show that in SFMCs, which 
express high levels of p75NTR, proNGF induces proin-
flammatory but not anti-inflammatory cytokine expres-
sion, and that this effect is mediated through its binding 
to p75NTR, suggesting that an active proNGF-p75NTR 
axis may play a proinflammatory role in inflamed joints.
dIsCussIOn
Although inflammation has been associated with a marked 
increase in the synthesis of NGF in tissues1 the effects of 
mNGF, its precursor proNGF and their receptor signal-
ling in regulating cells and mediators during inflamma-
tory responses are still largely unknown. In this study, we 
provide evidence that an altered balance between TrkA and 
p75NTR receptors and an active proNGF-p75NTR axis may 
contribute to sustain inflammation in chronic arthritis.
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Figure 5 proNGF and NGF activated different intracellular pathways. (A) The neutralisation of p75NTR using either a specific 
anti-p75NTR antibody (a-p75; 2.5 µg/mL) or using the specific pharmacological inhibitor LM11A.31 (10 nM), decreased 
interleukin (IL)-6 release in LPS-activated SFMC of patients with JIA (n=16) treated with proNGF. On the contrary, the blocking 
of TrkA with a neutralising antibody (a-TrkA; 3 µg/mL) did not affect IL-6 release. (B) Western blot shows an increased 
phosphorylation of p38 and JNK after 5 minutes of proNGF stimulation in LPS-treated SFMC. mNGF treatment did not affect 
the phosphorylation of these downstream molecules. The result is representative of one out of three independent experiments. 
Results of the densitometric analysis of all experiments are expressed as arbitrary units (AU). (C) In LPS-activated SFMC 
of three different patients with JIA, preincubation with the inhibitor LM11A-31 (10 nM), which blocks the binding of proNGF 
to p75NTR, abolished the phosphorylation of p38 and JNK induced after 5 minutes of proNGF addition. Results of the 
densitometric analysis of all experiments are expressed as arbitrary units (AU). *p<0.05, **p<0.01, ***p<0.001. JIA, juvenile 
idiopathic arthritis; LPS, Lipopolysaccharide; NGF, nerve growth factor; SFMC, mononuclear cells isolated from synovial fluids.
We found that mononuclear cells of patients with JIA are 
characterised by an increased expression of p75NTR and 
a concomitant decrease in TrkA, at both the mRNA and 
protein levels, resulting in a highly abnormal ratio between 
p75NTR and TrkA. The expression of p75NTR in JIA SFMC 
is 13 times that of TrkA, and even though in these cells there 
is an increase in TrkA expression compared with JIA PBMC, 
this is not sufficient to re-establish the balance between the 
two NGF receptors found in healthy controls, where TrkA is 
the more expressed receptor. In addition to this abnormal 
expression of p75NTR, we found in JIA mononuclear cells 
a parallel increase in the expression of sortilin, the core-
ceptor of p75NTR to which, as demonstrated in neuronal 
cells,27 it is structurally and functionally coupled. Since 
sortilin specifically binds the prosequence of proNGF and 
increases the affinity of p75NTR for proNGF,12 our results 
are indicative of the presence of a functional high-affinity 
proNGF receptor in JIA mononuclear cells.
Previous studies on patients with RA and JIA2 3 and 
experimental models of arthritis28 29 reported that NGF 
is enhanced in synovial tissues and fluids. However, the 
techniques available at the time of these studies were 
not able to discriminate between the different molec-
ular forms of NGF. Using western blot and newly devel-
oped ELISAs,20 we demonstrated in patients with chronic 
arthritis that proNGF is the highly prevalent form of NGF 
in the inflamed synovium and that it is actively synthesised 
by FLS more than by mononuclear cells. The prevalence 
of proNGF has also been reported in tissues of patients 
with neurodegenerative diseases, such as Alzheimer’s 
and Parkinson’s diseases,30 31 which are characterised by 
local tissue inflammation.32–34 The mechanisms affecting 
proNGF maturation in inflamed tissues are at present 
unknown. In the brain of patients with Down syndrome 
and Alzheimer’s disease, studies by Iulita and Cuello35 
showed a deficit in NGF extracellular metabolism that 
leads to proNGF accumulation. At present, there are no 
data suggesting that a similar mechanism could occur in 
peripheral tissues during an inflammatory response and 
further studies are needed.
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The presence of high levels of proNGF in peripheral 
tissues15 20 36 has recently been the focus of a number of 
studies since it is becoming clear that proNGF and mNGF 
have different, even opposite, effects on neuronal cells14 37 
and, as recently reported, also on macrophages.38
To characterise the effect of an active p75NTR axis 
on inflammation, we treated JIA SFMC ex vivo with 
either proNGF or mNGF. While in neurons the binding 
of proNGF to p75NTR/sortilin leads to apoptosis,27 
incubation of JIA cells with either proNGF or mNGF 
did not lead to changes in cell viability. In the absence 
of TLR stimulation, the addition of proNGF alone did 
not induce a significant increase in the expression of 
inflammatory cytokines in mononuclear cells of either 
patients with JIA or healthy controls, regardless of their 
level of p75NTR expression. In contrast, the addition of 
proNGF to LPS-activated SFMC leads to an increase in 
the expression of proinflammatory cytokines, such as 
IL-1β, IL-6, IL-8 and TNF-α, while mNGF addition did 
not induce inflammatory cytokine expression. The addi-
tion of proNGF to LPS-activated SFMC did not modify 
the expression of IL-10, an anti-inflammatory cytokine 
whose synthesis is instead specifically induced by mNGF 
in monocytes4 and in control PBMC, both cell types char-
acterised by high expression levels of TrkA. Consistent 
with this finding, the incubation of LPS-activated SFMC 
with proNGF significantly increased the phosphorylation 
of p38 and JNK, activating pathways involved in inducing 
inflammatory cytokine expression,39 while the addition of 
mNGF to LPS-activated SFMC did not have these effects. 
Therefore, in line with recent data on neurons40 and on 
PC12 cells,14 the biological effects and the signalling path-
ways activated in JIA cells by proNGF differ from those of 
mNGF. These data indicate that the binding of proNGF 
to p75NTR, but not of mNGF, is specifically involved 
in the induction of inflammatory cytokine expression. 
Confirming this hypothesis, we found that the blocking 
of p75NTR with a neutralising antibody or LM11A-31, a 
selective non-peptide ligand of p75NTR that specifically 
blocks the binding site of p75NTR for proNGF,26 specif-
ically inhibited phosphorylation of p38 and JNK and 
abolished the IL-6 production induced by proNGF, while 
the inhibition of TrkA did not affect IL-6 levels. A similar 
inhibitory effect of LM11A-31 on JNK phosphorylation 
has been described after LM11A-31 blocking of p75NTR 
in hippocampal neurons in an in vitro model of Alzhei-
mer’s neurodegeneration.41 The functional improve-
ment in motor function and coordination observed in 
a mouse model of spinal contusion injury after in vivo 
administration of LM11A-31 has been associated with a 
significant reduction in JNK activity in the spinal cord, 
further highlighting the central role of this pathway in 
proNGF/p75 NTR signalling.42
The molecular basis of the different, even opposite, 
effects of mNGF and proNGF that use the same receptor 
systems is not yet completely clarified. The most reason-
able explanation involves the different binding affinity 
of the two NGF forms, with mNGF showing the higher 
affinity for TrkA and proNGF for the p75NTR/sortilin 
complex.9 In our previous studies on human mononu-
clear cells and monocytes of healthy donors, expressing 
significantly more TrkA than p75NTR, the binding of 
mNGF to TrkA reduced inflammatory cytokine produc-
tion while increasing the release of anti-inflammatory 
cytokines. These effects on cytokine expression were asso-
ciated with the inhibition of nuclear NF-κB translocation, 
inhibition of GSK3 activity and induction of Akt.4 The 
anti-inflammatory effects of NGF on cytokine expression 
and on intracellular signalling pathways were abolished 
by blocking TrkA, but not p75NTR.4 Interestingly, Jiang 
and coworkers43 have reported that also mNGF, through 
binding to p75NTR in human dendritic cells that express 
p75NTR but not TrkA, induced cytokine expression 
and dendritic cell maturation by specifically activating 
p38 and NF-κB pathways. Altogether, these data suggest 
that, more than the relative concentrations of the two 
ligands (ie, mature and proNGF), it is the relative levels 
of expression of the two receptor systems (ie, TrkA and 
p75NTR/sortilin) that direct the immune cells towards 
a proinflammatory or an anti-inflammatory response. In 
a study using the PC12 neuronal cell line, it was shown 
that proNGF can have neurotrophic activity in primed 
PC12 or apoptotic activity in unprimed PC12, two cell 
conditions characterised by a different ratio of TrkA and 
p75NTR, further suggesting that the biological activity of 
proNGF is dependent on the relative expression levels of 
TrkA and p75NTR.44
In agreement with this hypothesis are our data on the 
differential effects of proNGF in LPS-activated cells on 
cytokine production determined by p75NTR expres-
sion levels. Indeed, the addition of proNGF to healthy 
donor cells, with higher TrkA than p75NTR expression, 
did not enhance inflammatory cytokine expression. In 
contrast, the addition of proNGF to JIA SFMC expressing 
higher levels of p75NTR led to enhanced production of 
inflammatory cytokines. It is therefore highly conceiv-
able that the high expression of p75NTR in immune cells 
coupled with high levels of proNGF, released by fibro-
blasts in inflamed synovium, may contribute to amplify 
the inflammatory response in chronic arthritis. It is worth 
noting that data consistent with this hypothesis have 
been reported in diabetic retinopathy. In human and rat 
retinas, high expression levels of p75NTR and decreased 
phosphorylation of TrkA are associated with a shift from 
mNGF to the immature proNGF form.45 46 Moreover, 
studies in experimental diabetes using p75NTR knockout 
mice have shown a reduced inflammatory response and a 
decrease in TNF-α release in the retina with a beneficial 
effect on glial activation and ganglion cell loss,47 further 
supporting the proinflammatory role of p75NTR.
An additional, although indirect, indication of the 
proinflammatory role of p75NTR was obtained from 
the analysis of p75NTR expression in patients with JIA 
divided into groups according to their subtype. We found 
that the levels of p75NTR expression are correlated with 
disease severity and activity as documented by the direct 
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correlation with JIA subtypes and with the number of 
active joints and CRP levels. Altogether these data point 
to a proinflammatory action of proNGF which is medi-
ated through its binding to p75NTR and not through 
TrkA.
In conclusion, this study provides new evidence for a 
role of p75NTR and its preferential ligand proNGF in 
amplifying inflammatory responses in chronic arthritides. 
The relative expressions of p75NTR and TrkA, as well as 
the relative concentrations of proNGF and mNGF forms, 
may regulate inflammatory responses and may represent 
an additional mechanism in the progression of inflam-
matory joint disease, with high levels of proNGF and high 
expression of p75NTR tilting the balance towards proin-
flammatory pathways. Inhibition of the p75NTR-proNGF 
axis and its effects on the proinflammatory loop should 
be investigated as a possible new therapeutic approach in 
chronic arthritis and in animal models. In this respect, 
the in vivo efficacy of LM11A-31, the non-peptide ligand 
that blocks the binding site of p75NTR for proNGF, has 
recently been demonstrated in animal models of spinal 
cord injury42 and Alzheimer’s disease.48 A clinical trial 
(NCT03069014) assessing the safety of LM11A-31-admin-
istration in patients with Alzheimer’s disease is currently 
ongoing.
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